Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(75.0%)

Phase 4

1(25.0%)

4Total

N/A(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05908448Completed

The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus

Role: collaborator

NCT03143816Phase 4Completed

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study

Role: collaborator

NCT04823312Not ApplicableUnknown

Evaluation of Medtronic DUO Extended Set

Role: lead

NCT01614262Not ApplicableCompleted

Examining The Role of CGM in T2DM

Role: collaborator

NCT02682940Not ApplicableTerminated

T1 Diabetes Hypoglycemia Prevention Pilot

Role: collaborator

All 5 trials loaded